Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.16T
Market cap1.16T
Price-Earnings ratio
43.49
Price-Earnings ratio43.49
Dividend yield
0.53%
Dividend yield0.53%
Average volume
3.44M
Average volume3.44M
High today
$1,238.00
High today$1,238.00
Low today
$1,203.14
Low today$1,203.14
Open price
$1,222.78
Open price$1,222.78
Volume
3.65M
Volume3.65M
52 Week high
$1,238.00
52 Week high$1,238.00
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.16T, Eli Lilly(LLY) trades at $1,228.26. The stock has a price-to-earnings ratio of 43.49 and currently yields dividends of 0.53%.

On 2026-06-29, Eli Lilly(LLY) stock moved within a range of $1,203.14 to $1,238.00. With shares now at $1,228.26, the stock is trading +2.1% above its intraday low and -0.8% below the session's peak.

Trading activity shows a volume of 3.65M, compared to an average daily volume of 3.44M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,238.00 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,238.00 and a low of $623.78.

LLY News

TipRanks 43m
FDA to Expedite Review of Eli Lilly’s New Manufacturing Facilities

Eli Lilly (LLY) is one of the first companies to be selected for a U.S. Food and Drug Administration (FDA) pilot program that’s designed to accelerate reviews o...

Reuters 1h
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports - Reuters

...

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports - Reuters
TipRanks 1h
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

Eli Lilly (LLY), Regeneron (REGN), Amneal (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will parti...

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
9.7%
Sell
6.5%

More LLY News

CNBC 2h
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Key Points Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in...

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
TipRanks 6h
Eli Lilly Stock Hits All-Time High as Weight-Loss Drug Sales Accelerate

The stock of Eli Lilly (LLY) hit an all-time high on June 29 as the pharmaceutical company’s weight-loss drug sales accelerate and excitement builds for upcomin...

Nasdaq 9h
Lilly Moves 7.1% Higher: Will This Strength Last?

Eli Lilly LLY shares ended the last trading session 7.1% higher at $1. The jump came on an impressive volume with a higher-than-average number of shares changin...

Lilly Moves 7.1% Higher: Will This Strength Last?
Nasdaq 3d
Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?

Eli Lilly (NYSE: LLY) is benefiting from its blockbuster weight loss treatment. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double D...

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?
Nasdaq 3d
Why Eli Lilly Stock Jumped to a New All-Time High Today

Key Points Eli Lilly's leukemia drug is making progress toward regulatory approval in the EU. The healthcare leader's weight-loss drugs will soon be more affo...

Why Eli Lilly Stock Jumped to a New All-Time High Today
Nasdaq 3d
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Key Points Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative. Novo’s steady insulin cash flows and n...

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?
Simply Wall St 3d
Eli Lilly Could Be 24% Undervalued If Its Growth Narrative Holds

Eli Lilly (LLY) is back in focus for investors after its recent share performance, with the stock closing at $1,127.69 and sitting within a large pharmaceutical...

Eli Lilly Could Be 24% Undervalued If Its Growth Narrative Holds

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.